I saw this on a thread on PR. (Yes if you're banned you can still see public threads ).
Biosimilars of rituximab Posted 27/02/2015
Last update: 30 October 2015
Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. Rituximab destroys B cells and is therefore used to treat diseases that are characterized by excessive number of B cells, overactive B cells or dysfunctional B cells. This includes many lymphomas, leukaemias, transplant rejection and autoimmune disorders.
The originator product, Roche’s MabThera/Rituxan (rituximab), was approved by the US Food and Drug Administration (FDA) in November 1997 and by the European Medicines Agency (EMA) in June 1998 . MabThera/Rituxan had sales of CHF 5.7 billion (Euros 5.2 billion) in 2014, therefore, many companies are working on biosimilars of the drug, see Table 1.
The patents on MabThera/Rituxan expire in the US in September 2016 and in Europe in February 2013 . Some of the rituximab biosimilars and non-originator biologicals* approved or in development are presented in Table 1.